The company, which now ranks as a startup with a valuation of more than $1 billion, will use the new funds to develop CRISPR-based therapeutics.
The point-of-care system can detect SARS-CoV-2 in unprocessed patient saliva in about an hour, according to the researchers.
The modified guide RNAs increased CRISPR editing efficiencies two- to fivefold over the editing efficiency achieved with unmodified guides, the researchers said.
Innovations in the liquid biopsy and oncology space gained investors' attention, leading to a spike in acquisition deals in the first half of the year.
The company hopes to complete the trial in early 2022 and submit data to the FDA for approval of its assay, which could compete with Exact Sciences' Cologuard.
The researchers said their approach could be used to predict disease onset and, ultimately, to identify early preventive interventions.
Johns Hopkins researchers have developed a single-cell, multispectral imaging platform called AstroPath for precise pathological analysis of cancer specimens.
Synthetic biology and CRISPR have enabled researchers to develop wearable sensors that can detect a variety of viruses and bacteria, including SARS-CoV-2.
The GAIN/iCat2 study and the Pediatric MATCH trial showed that molecular data has a significant impact on treatment recommendations for kids with cancer.
The method evaluates the editing specificity of cytosine base editors by detecting CBE-induced off-target sites across the genome.